During the last few sessions the technical situation of Pfizer It has improved. The stock, after leaning on the solid graphic support at $25.20, in fact made a quick leap forward and rose towards the psychological threshold of $29. Quantitative analysis records a strengthening of bullish pressure, with the main reference moving averages found below the price trend. Before being able to attempt a new extension (which will have a first target in the 29.40-29.45 area and a second target at 29.70-29.75 dollars) a short consolidation pause is however likely. Only a return below $27.20 could reverse the recent progress and provide a bearish signal.
From an operational point of view, the following financial instruments can be used:
– a Turbo Long with KnockOut level at $20.33 and leverage 4;
– a Fixed Leverage SG Certificate Long x2;
– a Covered Warrant SG Call with base 30 and expiring on 21 June 2024.
WARNING
This article was written independently by MFIU-Milano Finanza Intelligence Unit on the basis of sources deemed reliable. The article is aimed at offering concise merely informative and illustrative ideas on the use of financial instruments without therefore representing a solicitation for public savings, nor an invitation to subscribe or purchase the securities nor even a consultancy, recommendation and/or investment advice. . Therefore, any investment decision and the related risk remain the responsibility of the investor, who is strongly recommended to contact the issuer, before making any decision, for any more appropriate advice, in-depth analysis and evaluation in order to make informed choices, inviting you to always read the regulatory documentation on the issuer’s website. Consequently, and in any case, neither MFIU nor IG, including the companies of the IG Group, can be held responsible in any way for the consequences that could arise from any use that the reader may make of the contents of the article.
For information on MFIU-Milano Finanza Intelligence Unit as a producer of recommendations, as well as on the presentation of recommendations and on the positions and conflicts of interest of the producer, please click on this link
